Bio Sequence

Strategy for Retrieving Bispecific Antibody Sequences

19 September 2023
2 min read

Bispecific antibodies (BsAbs) have two distinct binding domains that can bind to two antigens or two epitopes (an antigen part) of the same antigen simultaneously. Using the Patsnap Bio Sequence Database for bispecific antibody sequence retrieval is recommended. This database covers comprehensive literature and publicly disclosed antibody sequences, with a separate module for antibody sequence retrieval. Here are the steps to access bispecific antibody sequences. 

1. First, click on the link to apply for a free account registration in the Bio database. Click "Antibodies" in the left sidebar and enter the antibody sequence retrieval. Input the light/heavy chain/variable region sequence or CDR sequence of one of the target A antibodies of the bispecific antibody.

2. Begin the search and keep intersection results in your workspace, creating a new folder labeled "A."

3. In the same manner, retrieve the light/heavy chain/variable region sequence or CDR sequence of target B antibody, and name the search results as a new folder "B."

4. By taking the patent intersection of folders A and B, you can obtain patents related to bispecific antibody sequences. If necessary, you can also utilize keywords for further filtering.

It is important to note that Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated, illuminating structural modifications to provide the most accurate sequence data and boost sequence retrieval efficiency.

Free registration is available for the Bio biological sequence database: https://bio-patsnap-com.libproxy1.nus.edu.sg. Act now to expedite your sequence search tasks.

Edgewise Therapeutics commences Phase 1 human trial for EDG-7500, a promising treatment for Hypertrophic Cardiomyopathy and severe Cardiac Diastolic Dysfunction
Latest Hotspot
3 min read
Edgewise Therapeutics commences Phase 1 human trial for EDG-7500, a promising treatment for Hypertrophic Cardiomyopathy and severe Cardiac Diastolic Dysfunction
19 September 2023
Edgewise Therapeutics initiates its first-in-human Phase 1 trial for EDG-7500, the primary clinical contender for Hypertrophic Cardiomyopathy and other severe Cardiac Diastolic Dysfunction conditions.
Read →
"Super drugs" for treating cancer and AIDS: Chemokines family
Advanced Tech.
10 min read
"Super drugs" for treating cancer and AIDS: Chemokines family
19 September 2023
Chemokines, also known as chemotactic cytokines, are a group of factors that, in conjunction with their cell surface receptors, induce the directed migration of leukocytes.
Read →
The NC318 Phase 2 trial, in Combination with Pembrolizumab, shows clinical activity in treating patients with advanced NSCLC
Latest Hotspot
4 min read
The NC318 Phase 2 trial, in Combination with Pembrolizumab, shows clinical activity in treating patients with advanced NSCLC
19 September 2023
NextCure Inc. and Yale Cancer Center announced Phase 2 trial results today, indicating a combined NC318 and Pembrolizumab regimen is beneficial for advanced non-responsive PD-1 non-small cell lung cancer patients.
Read →
Myeloid Therapeutics begins administering MT-302, a new TROP2-focusing RNA CAR, for advanced or metastatic epithelial tumors
Latest Hotspot
3 min read
Myeloid Therapeutics begins administering MT-302, a new TROP2-focusing RNA CAR, for advanced or metastatic epithelial tumors
19 September 2023
Myeloid Therapeutics, a clinical-stage cancer treatment company, has given the first dose of MT-302 to a patient in a Phase 1 trial for advanced or metastatic epithelial tumors.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.